17 October, 2019
Wong & Partners, the member firm of Baker McKenzie in Malaysia, are advising Gribbles Pathology (Malaysia) Sdn. Bhd. ("GPMSB") in connection with its proposed MYR 42 million acquisition of a 100% stake in MPath Sdn. Bhd. ("MPath") and its subsidiaries from Malaysian Genomics Resource Centre Berhad. GPMSB is indirectly-owned by Pathology Asia Holdings Pte. Ltd., which is a part of TPG, a leading global private investment firm.
MPath has 3 subsidiaries, namely Clinipath (Malaysia) Sdn. Bhd. ("CMSB"), Clinipath Capital Sdn. Bhd. ("CCSB") and Medical Scan Sdn. Bhd. ("MSSB"). CMSB is the main operating subsidiary and its principal activities are the provision of pathological and medical laboratory services in Malaysia. CCSB’s principal activity is that of renting out commercial properties to CMSB for its laboratories. MSSB’s principal activity is the provision of medical laboratory services in Malaysia. MSSB had ceased its business operation since 1 January 2017.
Wong & Partners is acting as lead transaction counsel for GPMSB. Partner Munir Abdul Aziz led the team, supported by associates Yee Yin Tang and Kimberly Ng.
"We are honoured to represent and work with our client in this significant transaction in the pathological and medical laboratory services industry. We are fortunate to have been able to apply our healthcare industry capabilities in a growing segment of the market, and to help our client build on its strong footprint in Asia,” said Munir.
Deal summary
Wong & Partners, the member firm of Baker McKenzie in Malaysia, are advising Gribbles Pathology (Malaysia) Sdn. Bhd. ("GPMSB") in connection with its proposed MYR 42 million acquisition of a 100% stake in MPath Sdn. Bhd. ("MPath") and its subsidiaries from Malaysian Genomics Resource Centre Berhad. GPMSB is indirectly-owned by Pathology Asia Holdings Pte. Ltd., which is a part of TPG, a leading global private investment firm.
Value
RM 42 million
Lead partner
Munir Abdul Aziz
Supporting lawyers
Yee Yin Tang and Kimberly Ng (Associates)
